| Uf Health Shands Hospital | |
| 1600 Sw Archer Rd, Gainesville, Florida 32610 | |
| (352) 265-8000 | |
| Name | Uf Health Shands Hospital |
|---|---|
| Type | Acute Care Hospital |
| Location | 1600 Sw Archer Rd, Gainesville, Florida |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 100113 |
| NPI Number | 1235214834 |
| Organization Name | UNIVERSITY OF FLORIDA |
| Address | 1600 Sw Archer Rd, Room D2-11, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 352-395-8013 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1285914374 |
| Organization Name | UNIVERSITY OF FLORIDA |
| Address | 1600 Sw Archer Rd, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 352-265-0622 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1518336643 |
| Organization Name | UF NEUROSURGERY |
| Address | 1600 Sw Archer Rd, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 352-273-9000 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1639432875 |
| Organization Name | UNIVERSITY OF FLORIDA |
| Address | 1600 Sw Archer Rd, Uf Department Of Pathology, Gainesville, FL 32610 |
| Hospital Type | Chronic Disease Hospital |
| Phone Number | 443-629-9410 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1689753733 |
| Organization Name | UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE |
| Address | 1600 Sw Archer Rd, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 352-256-0261 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1891810206 |
| Organization Name | SHANDS HOSPITAL |
| Address | 1600 Sw Archer Rd, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 352-392-8013 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| NPI Number | 1932538089 |
| Organization Name | UNIVERSITY OF FLORIDA |
| Address | 1600 Sw Archer Rd, B100296, Room Hd-513, Gainesville, FL 32610 |
| Hospital Type | General Acute Care Hospital - Children |
| Phone Number | 352-273-8234 |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
| Able to receive lab results electronically | Yes |
| Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.
Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.
› Verified 9 days ago
Uf Health Shands Hospital Acute Care Hospital Location: 1600 Sw Archer Rd, Gainesville, Florida 32610 Phone: (352) 265-8000 | |
North Florida Regional Medical Center Acute Care Hospital Location: 6500 Newberry Rd, Gainesville, Florida 32605 Phone: (352) 333-4100 |